Despite significant progress in the management of the HIV virus that causes AIDS, today’s best treatments do not totally eradicate the virus. The virus’ ability to develop resistance to current antiretroviral therapy (ARVT) means the therapy needs to be changed if it is to continue to be effective.
By focusing on the genotype of the virus – information which is inexpensive and easily available – and combining this with clinical information about the patient, researchers behind the EU-funded EuResist project developed new mathematical prediction models.
"In cases where there is a long history of resistance, this is an indicator of death, so it is important to try all the possibilities," says Francesca Incardona, EuResist’s coordinator. For non-crucial cases, this may help reduce the cost of the therapy, by choosing the right combination of drugs that work for the longest time, she suggests.
EuResist’s key achievement was to combine data from HIV databases in Italy, Sweden and Germany, giving "probably the largest database of its kind in the world", according to Incardona.
Combining the world’s largest databases and newly created software has given the project the ability to predict how the HIV virus will react in a certain person given a certain combination of drugs. And this performance is better than the current state-of-the-art predictive systems available to medical researchers, says Incardona, who is based at Italian company Informa.
The achievements of EuResist translate into better medicine, lower treatment-related toxicity and cost savings – giving considerable hope to the 40 million people infected with the virus worldwide.
Strength in numbers
Combining the data from the three national databases was the first and probably most important step, suggests Incardona. It was not only a cyber-merger, but a physical merger, too.
All of the information is now located in what the EU researchers claim as the world’s biggest database of AIDS resistance-related information with more than 18,000 patients, 64,000 therapies, and 240,000 viral mode measurements.
With all this data, medical researchers and doctors can now predict what would happen if a patient with a certain type of virus and certain viral load is given a certain combination of ARVT.
Putting the jigsaw together
Accurate and reliable prediction of future responses to treatment is based on three basic pieces of information: A quantification of the viral load, a definition of the viral genotype, and the viral load after eight weeks of treatment.
The researchers then include other information, such as how the virus is transmitted – sexual or via a blood transfusion – the gender of the person, the sexual preference of the person, whether they are drug abusers and other.
Three different but complementary programmes were developed by the project partners. Each uses the same type of mathematical model to classify a given drug combination as successful or unsuccessful, but is fed with different information. In fact, three approaches are used to extract data from the database to account for different aspects of the disease evolution.
So how well do these engines perform? The researchers evaluated them separately (and in combination) and found that EuResist’s model was 76 percent accurate, which was better than the state-of-the-art HIV resistance database at Stanford University, USA.
Compared to the existing systems, which calculate only according to single drugs, the EuResist model can account for combinations of therapies, bringing the results closer to everyday situations.
Sharing the knowledge
The EU-funded project is drawing to a close but the partners are determined to create a legacy. Researchers from the three academic partners – Italy’s University of Siena, Sweden’s Karolinska Institute, and Germany’s Max Planck Institute – together with Informa have created the EuResist Network GEIE, a European not-for-profit organisation.
The aim of the network is to maintain the database and make both it and the predictive programs available to medical researchers and doctors all over the world.
At the centre of this network is a web interface, which Incardona says will be free on the web for the global medical community.
And the potential of the project does not stop with the virus that causes AIDS. The breakthroughs from EuResist may also be applicable to every other type of virus that develops resistance to similar prolonged antiretroviral treatments, like hepatitis B and C.
EuResist received funding from the EU's Sixth Framework Programme for research.
Christian Nielsen | alfa
The TU Ilmenau develops tomorrow’s chip technology today
27.04.2017 | Technische Universität Ilmenau
Five developments for improved data exploitation
19.04.2017 | Deutsches Forschungszentrum für Künstliche Intelligenz GmbH, DFKI
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences